Introduction {#sec1_1}
============

Frontotemporal lobar degeneration (FTLD) is a common form of early-onset dementia in patients younger than 65 years \[[@B1]\]. Three major clinical syndromes are recognised: behavioural variant frontotemporal dementia (bvFTD) with predominant behavioural and executive problems; semantic dementia (SD) presenting with loss of semantic memory for words and objects, and progressive non-fluent aphasia (PNFA) presenting with progressive loss of speech and non-fluent speech output \[[@B2]\]. Around 15% of patients with FTLD also develop amyotrophic lateral sclerosis (ALS; FTLD-ALS) \[[@B3]\].

FTLD and ALS are known to form an overlapping disease spectrum at clinical level \[[@B3]\]. Pathologically, they show underlying TAR DNA-binding protein 43 (TDP-43)-positive inclusions \[[@B4]\]. Recently, the causative gene of the chromosome 9-linked FTLD and ALS has been mapped to a hexanucleotide (GGGGCC) repeat expansion within the gene *C9ORF72* \[[@B5],[@B6]\]. The repeat expansion has been reported to account for 25% of familial FTLD worldwide \[[@B7]\]; therefore, it seems the most common cause of FTLD. In Finland, the *C9ORF72* expansion is exceptionally common in patients with the FTLD-ALS disease spectrum, explaining nearly 50% of familial FTLD \[[@B6]\]. Irrespective of the population or family history, all repeat expansion carriers seem to share a Finnish founder risk haplotype across the mutation locus \[[@B7],[@B8],[@B9]\]. The first detailed *C9ORF72* genotype-phenotype descriptions have suggested a core phenotype for the *C9ORF72*-associated FTLD \[[@B10],[@B11]\], albeit a wide variation in clinical phenotype, as well as in demographic characteristics. The aim of our study is to provide a detailed evaluation of the clinical profile of Finnish patients with FTLD caused by the *C9ORF72* repeat expansion, and to contrast our findings with the suggested core phenotype. Furthermore, the role of the apolipoprotein E *(APOE)* genotype as a potential disease modifier was assessed.

Methods {#sec1_2}
=======

Study Population {#sec2_1}
----------------

The cohort consisted of 73 Finnish patients (mean age ± standard deviation at onset, 58.5 ± 7.3 years; age range 38-79; 45% men) diagnosed with FTLD \[[@B2]\] at the Memory Clinic of the Oulu University Hospital, Finland, during the period 1999-2010, and who were clinically followed up until the end of 2011. The mean follow-up period was 3.5 ± 2.8 years (range 0.1-11.8). The cohort included 46 (63%) patients with bvFTD, 20 (27%) with PNFA and 7 (10%) with SD. Concomitant ALS was diagnosed in 8 (11%) patients \[[@B12]\]. FTLD was classified as familial when at least one first-degree relative was reported to suffer from neurodegenerative dementia. Family history was positive for dementia in 26 (36%) cases, for ALS in 3 (4%), and for both in 2 (3%) cases. In those with familial presentation, there were 3 unrelated sibling pairs. Thus, when taking into account only 1 sibling per family, there were altogether 70 apparently unrelated FTLD patients in the cohort. Mutations in the known FTLD genes *MAPT*, *PGRN* and *CHMP2B* were previously excluded \[[@B13],[@B14],[@B15]\]. The cohort was screened for the *C9ORF72* repeat expansion as a part of the *C9ORF72* mutation discovery study \[[@B6]\] that included 75 patients from our cohort of FTLD patients. The research protocols were approved by the Ethics Committee of the Northern Ostrobothnia Hospital District, following the principles of the Declaration of Helsinki. All patients agreed to participate in the study, and blood samples were obtained after written informed consent from patients and/or their legal representatives.

Neurological Assessment {#sec2_2}
-----------------------

Clinical evaluation and follow-up of the patients were carried out by two neurologists. Major behavioural (apathy, disinhibition, aggression, manic behaviour and stereotyped behaviour) and psychiatric symptoms (psychiatric depression, psychosis, delusions, hallucinations and paranoia) were recorded, as well as significant language impairment and extrapyramidal signs (tremor, bradykinesia, rigidity and gait impairment). The first Mini-Mental State Examination (MMSE) score at presentation was also present in the patient records. The *APOE* genotype was determined for all patients as described previously \[[@B16]\].

Neuropsychological Assessment {#sec2_3}
-----------------------------

Neuropsychological tests were initially carried out as a part of clinical diagnostics or follow-up, and therefore no uniform neuropsychological test battery was used (see online suppl. methods [1](#S1){ref-type="supplementary-material"} for a detailed list of tests; for all online supplementary material, see [www.karger.com/doi/10.1159/000351859](http://www.karger.com/doi/10.1159/000351859)). Impairment in concentration, executive function, verbal knowledge, literacy, verbal memory, non-verbal knowledge, non-verbal memory, spatial orientation, constructive and fine motor skills were each rated on a five-stage scale (scale 0-4), the weakest fifth percentiles (score 0) being those with a poor performance in tests and who could not be assessed psychometrically in that section. A group median was calculated for each sector. The median was selected as the summary statistic as it is less susceptible to the effects of outliers in small amounts of data. Medians were determined for two groups: (1) the analysed *C9ORF72* expansion group as a whole (n = 20; mean duration of symptoms at evaluation, 2.6 ± 2.5 years) and (2) a subgroup of 9 bvFTD patients in whom the early cognitive profile was available (mean duration of symptoms at evaluation, 2.6 ± 3.3 years). The remaining 11 *C9ORF72*-positive patients were excluded from the latter analysis because of dementia-staged disease at evaluation and/or prominent language symptoms.

Visual Assessment of Neuroimaging {#sec2_4}
---------------------------------

The MR images of 12 patients with *C9ORF72* expansion were available for retrospective analysis; 1 patient was imaged at 0.23 T and the rest at 1.5 T. MR images were rated for frontal, temporal and parieto-occipital atrophy on a scale of 0-3; both sulcal and ventricular dilatation were taken into account \[[@B17]\]. Medial temporal lobe atrophy was assessed using Scheltens\' scale (0-4) \[[@B18]\]. Vascular white matter lesions were scored in a manner where periventricular hyperintensity and separate deep white matter hyperintensities are rated separately on a 0-3 rating scale \[[@B19]\]. Assessment of sulcal and ventricular dilatation was mainly based on axial T2-weighted 2-dimensional fluid-attenuated inversion recovery images, and analysis of medial temporal lobe atrophy was based on coronal T1-weighted 3-dimensional images.

Axial CT images of 4 expansion carriers lacking MR images were available for analysis. Frontal, temporal and parieto-occipital atrophy was assessed in the same way as in the MR images. White matter changes were roughly evaluated as absent/mild/moderate/severe. Medial temporal lobe atrophy could not be assessed from the CT scans. Both MR and CT images were also evaluated for cerebellar atrophy. At the time of brain imaging, the mean duration of symptoms was 3.7 ± 3.7 years (range 0.5-15.0).

Neurophysiological Assessment {#sec2_5}
-----------------------------

Routine 21-channel digital EEG was recorded in 7 expansion carriers. Quantitative EEG spectral analysis could be carried out retrospectively in 3 patients. Absolute and relative power was calculated for the delta, theta, alpha and beta frequency bands for each channel. Electroneuromyography (ENMG) examination was carried out in 4 expansion carriers, and in two of them motor-evoked potentials by transcranial magnetic stimulation (TMS-MEP) were also recorded.

Neuropathological Examination {#sec2_6}
-----------------------------

Formaldehyde-fixed and paraffin-embedded post-mortem brain and spinal cord tissues were available for analysis in 2 expansion carriers (Nos. 16 and 17) and in 1 non-carrier (No. 23) for comparison. Immunohistochemistry on 6-µm histological sections of medial frontal gyrus, superior and medial temporal gyrus, hippocampus, brain stem, cerebellum and spinal cord was performed with antibodies against hyperphosphorylated tau, Aβ, α-synuclein, p62 and phosphorylated TDP-43 (p-TDP-43) (see online suppl. methods [2](#S1){ref-type="supplementary-material"} for detailed conditions). The extent of the p62 and p-TDP-43 pathology was rated for each region semiquantitatively. The pathology of FTLD-TDP was subtyped based on the harmonised classification system \[[@B20]\].

Statistical Analysis {#sec2_7}
--------------------

Differences between two groups were assessed using Student\'s t test for continuous variables after testing for normal distribution and Pearson\'s χ^2^ and Fisher\'s exact test for categorical variables, as appropriate. Using logistic regression analysis, crude and adjusted odds ratios (ORs) were calculated (the latter adjusted by the variables included in the model) with 95% confidence intervals (CIs) to evaluate the association of the *C9ORF72* repeat expansion with concomitant ALS and family history of dementia or ALS. Survival time was analysed by the Kaplan-Meier method. Moreover, the resulting curves for the expansion carriers and non-carriers were compared with the log-rank test. Survival time was defined as time from symptom onset to death. Patients who were alive at the end of the follow-up period were censored. The significance threshold was 0.05. Analyses were performed using SPSS software version 16.0 (SPSS, Inc., Chicago, Ill., USA).

Results {#sec1_3}
=======

Demographic and Clinical Features {#sec2_8}
---------------------------------

Overall, the *C9ORF72* expansion was detected in 22 of 73 patients, of which 13 were familial cases and 9 sporadic. See table [1](#T1){ref-type="table"} for demographic and clinical characteristics of the 22 expansion carriers. The expansion was present in 20 of 70 (29%) probands. Moreover, 43% of the probands with a family history of dementia and 21% of the apparently sporadic cases carried the expansion. To exclude bias in the association analysis, only 1 sibling per family was randomly included in the analyses, i.e. 20 carriers and 50 non-carriers. Detailed results of the association analyses are given in table [2](#T2){ref-type="table"}. In expansion carriers, age at disease onset ranged from 46 to 70 years (mean 58.3 ± 5.9 years). Age at disease onset and gender distribution were similar in expansion carriers and non-carriers. Conversely, a significant difference was observed in the family histories of the two groups. A family history of dementia was common in expansion carriers (50% of carriers vs. 26% of non-carriers, p = 0.05; crude OR = 2.8, 95% CI 1.0-8.4). In cases of family history of dementia or ALS, the OR for *C9ORF72* expansion was 3.5 (95% CI 1.2-10.3; p = 0.02), and when adjusted for concomitant ALS, the odds were even higher (OR = 5.2, 95% CI 1.5-17.9). bvFTD was the most common clinical phenotype among expansion carriers (n = 14, 70%), while there were 6 (30%) patients with PNFA and none with SD. Among non-carriers, the phenotype distributions were 58, 28 and 14%, respectively (p = 0.35). Survival of FTLD patients without concomitant ALS did not differ between carriers and non-carriers (p = 0.92). Interestingly, we detected 1 expansion carrier (No. 14) with an extremely long disease course of nearly two decades.

Concomitant ALS was diagnosed in 6 (30%) expansion carriers versus 2 (4%) non-carriers (p = 0.005) and was associated with increased odds of having the expansion (crude OR = 10.3, 95% CI 1.9-56.7). The association was even more pronounced when adjusted for family history of dementia or ALS (OR = 16.4, 95% CI 2.6-104.1). ALS was associated with bvFTD in 4 expansion carriers and with PNFA in 2. The symptoms of ALS were present or developed within 1 year after the first FTLD symptoms. The site of ALS onset was bulbar in 5 (83%) expansion carriers and spinal in 1 (17%). The only 2 non-carriers with concomitant ALS had spinal onset of the disease.

Detailed clinical data were available for 68 probands (19 carriers and 49 non-carriers). Among the first symptoms, relative-reported memory complaints were present in 13 (68%) carriers and in 36 (74%) non-carriers (p = 0.68). At the time of referral, the mean MMSE score was similar in both groups (table [2](#T2){ref-type="table"}). During the disease course, mild extrapyramidal symptoms were present in 5 (26%) carriers and 10 (20%) non-carriers (p = 0.75). Prominent behavioural symptoms were common in both groups (84 vs. 88%; p = 0.70). Apathy (53 vs. 61%), stereotyped behaviour (42 vs. 39%) and disinhibition (37 vs. 12%) were the most common behavioural symptoms. Problems in speech and language were also often encountered (84 vs. 69%; p = 0.21). There was a history of major psychosis in 4 (21%) expansion carriers. Psychosis was their leading symptom, and bvFTD was diagnosed within 1-5 years after psychosis. Delusions and auditory hallucinations were the most common psychiatric symptoms among expansion carriers; none had visual hallucinations. Psychosis was also diagnosed in 5 (10%) non-carriers (p = 0.25). Preceding the diagnosis of FTLD, major depression was suspected in both groups (16% of carriers vs. 20% of non-carriers; p = 0.99). None of the patients with psychosis developed concomitant ALS.

Cognitive Features {#sec2_9}
------------------

Analysis of the early cognitive profile revealed that severe executive dysfunction was already present at early stages of the disease (scale 1/4) (fig. [1b](#F1){ref-type="fig"}). Constructive skills, non-verbal knowledge and memory were also substantially affected (2/4). When the *C9ORF72* group was analysed as a whole, there was a substantial fall in all neuropsychological domains except literacy (fig. [1c](#F1){ref-type="fig"}). Concentration declined rapidly in all cases (0/4) and was the most severely affected domain besides executive functions (1/4). Deficits in fine motor skills, non-verbal knowledge, non-verbal memory as well as verbal knowledge were also salient (2/4). Verbal memory was slightly affected (3/4).

Neuroimaging Features {#sec2_10}
---------------------

The results of visual analyses of brain MR and CT images of the *C9ORF72* expansion carriers are summarised in online supplementary table [1](#S1){ref-type="supplementary-material"}. In the analyses, no uniform type of atrophy was detected. However, trends towards two different types of atrophy were observed: one with prevalent frontotemporal cortical atrophy often associated with frontal horn dilatation (fig. [2a, b](#F2){ref-type="fig"}), and the other with more generalised and prominent ventricular dilation (fig. [2c, d](#F2){ref-type="fig"}). Cortical atrophy also extended occasionally to the parieto-occipital region (fig. [2g, h](#F2){ref-type="fig"}). Moderate-to-severe ventricular enlargement was detected in 10 of 16 cases, it was mainly frontal and showed various combinations. Atrophy was mainly symmetrical. Medial temporal lobe atrophy varied from grade 0 to 3. Signs of minor cerebellar degeneration were only rarely found. Mild changes were detected in the white matter.

Neurophysiological Features {#sec2_11}
---------------------------

Two patients with repeat expansion developed epileptic seizures during the disease course. EEG findings were abnormal in 4 of 7 patients with *C9ORF72* expansion. Generalised slowing of background activity was detected in 2 patients. Two patients showed intermittent delta-theta activity in the left temporal region. Quantitative EEG spectral analysis of 3 patients did not show any further abnormal activity. In 2 patients, the ENMG findings revealed clinically definite ALS \[[@B12]\]. In the remaining 2 patients, abnormal bulbar ENMG and TMS-MEP confirmed the diagnosis.

APOE Allele {#sec2_12}
-----------

There was no statistically significant difference in the *APOE* ε4 allele frequency between the expansion carriers and non-carriers (20 vs. 18%; p = 0.78), nor were there significant differences in the *APOE* ε2 allele frequency (10 vs. 6%; p = 0.62). In the *C9ORF72* expansion group, *APOE* ε4 carriers were found both in patients with and without ALS (67 vs. 21%). Among expansion carriers, mean age at onset was 61.1 ± 5.7 years in *APOE* ε4 carriers and 56.8 ± 5.6 years in *APOE* ε4 non-carriers (p = 0.11).

Neuropathology {#sec2_13}
--------------

Neuropathological findings are summarised in table [3](#T3){ref-type="table"}. The PNFA patient (No. 16) showed an extremely atrophic neocortex and hippocampus on routine staining. One bvFTD-ALS patient (No. 17) had neuronal loss in the frontal cortex and also in the temporal neocortex and hippocampus to a lesser extent, while the other (No. 23) showed no atrophic changes in routine staining. Macroscopically, there was no pronounced cerebellar atrophy in any of these patients. However, the PNFA patient showed cerebellar gliosis and scarce Purkinje cells. The 2 cases with concomitant ALS had degeneration of hypoglossal nuclear neurons and spinal anterior horn cells. Occasional tau-positive neurons and neuropil threads in the hippocampus were seen in the expansion carrier (No. 17).

Immunohistochemistry for p-TDP-43 and p62 labelled neuronal cytoplasmic inclusions (NCIs), dystrophic neurites and occasional glial cytoplasmic inclusions in a wide range of brain regions. Of note, in the neocortex, p62 staining was less intense than p-TDP-43 staining, whereas in the hippocampus the stainings were of similar intensity. The patient with PNFA (No. 16) had FTLD-TDP type B pathology, whereas one of the patients with bvFTD-ALS (No. 17) had type A. The most specific findings as regards the expansion carriers were p62-positive, p-TDP-43-negative NCIs in cerebellar molecular and granular layers. In the cases with concomitant ALS, a p-TDP-43-positive lower motor neuron pathology was detected, yet on a small scale for the expansion carrier. Pyramidal tract pathology was also detected in the patient without clinical ALS.

Discussion {#sec1_4}
==========

The *C9ORF72* repeat expansion explains nearly 50% of familial and 30% of all FTLD cases in the Finnish population. The frequency of the *C9ORF72* expansion in Finland is among the highest in the world, and the sporadic form of the disease is also relatively common, as the mutation has been detected in 19% of cases of sporadic FTLD \[[@B6],[@B7]\]. The high frequency of the *C9ORF72* expansion is likely to reflect the Finnish population history. Haplotype analysis of *C9ORF72* expansion carriers has suggested that all patients with the expansion, both familial and sporadic cases, share a common Finnish founder risk haplotype \[[@B7],[@B8],[@B9]\].

bvFTD was the most common phenotype in patients with repeat expansion. Moreover, one third of the patients presented with PNFA, the frequency being similar in non-carriers. SD was absent in the *C9ORF72* expansion group. In previous reports, PNFA has been rare or absent in patients with *C9ORF72* expansion \[[@B10],[@B11],[@B21]\]. A variety of salient behavioural symptoms as well as major psychiatric symptoms were found in both groups. Among our expansion carriers, major psychosis was diagnosed in 21% of the patients, and it is noteworthy that psychosis may be the first symptom in a *C9ORF72* carrier, even years before other symptoms occur. Both mild and florid psychotic symptoms have been reported to be common in *C9ORF72* expansion carriers \[[@B10],[@B21],[@B22]\]. However, it is notable that patients without repeat expansion also presented with major psychosis with a frequency not statistically different from expansion cases.

As expected, ALS was more common in our FTLD patients with *C9ORF72* expansion than in those without \[[@B5],[@B6]\]. The bulbar-onset type of ALS seems to be associated with the expansion \[[@B21],[@B22],[@B23],[@B24],[@B25]\], and a similar trend was also detected in our study. The repeat expansion did not significantly affect survival in FTLD patients without ALS. Nonetheless, the number of deceased patients was low in our cohort. To date, *C9ORF72* expansion has not been associated with shorter disease duration in pure FTLD cases \[[@B24]\], in contrast to *C9ORF72*-linked ALS \[[@B23],[@B24],[@B26],[@B27]\].

The MRI findings did not reveal any uniform profile of atrophy in patients with repeat expansion. However, two distinct types of atrophy could be extracted: one with prevalent frontal cortical atrophy and the other with more generalised ventricular dilation. A similar ventricular enlargement has been reported in a longitudinal MRI analysis of expansion carriers \[[@B10],[@B11],[@B28]\]. In general, atrophy was symmetrical, which is consistent with previous reports \[[@B10],[@B11],[@B29],[@B30]\]. In voxel-based and volumetric MRI analyses, *C9ORF72* expansion groups have been characterized by widespread and varying patterns of atrophy, especially in the frontal and also in the temporal lobes, spreading even further to the parietal and occipital lobes and to the cerebellum \[[@B11],[@B28],[@B30]\]. In our cohort, parietal atrophy was also evident in some cases, whereas distinct cerebellar atrophy was not detected. While we were not able to detect cerebellar atrophy in the visual MRI analysis, the detection of p62-positive cerebellar inclusions supports the role of the cerebellum as an important region of *C9ORF72*-associated pathology \[[@B31]\]. However, in this study, there was no evidence of clinical cerebellar motor symptoms. The role of cerebellar atrophy and p62-positive inclusions is still unknown in *C9ORF72* expansion carriers.

Phenotypic variation is wide in *C9ORF72* expansion carriers \[[@B29]\], and the possible disease-modifying factors are still unknown. *APOE* ε4 has been shown to enhance brain atrophy in disease-specific regions in FTLD patients \[[@B32]\]. More recently, in an FTLD-ALS sibling pair linked to *C9ORF72* expansion, the *APOE* ε4 homozygous patient has been shown to have more severe cognitive behavioural symptoms and neuropathology than the patient with ε3 homozygosity \[[@B33]\]. In our study, the ε4 allele did not seem to contribute to the phenotype. Nevertheless, the role of *APOE* as a potential disease modifier in *C9ORF72*-associated FTLD-ALS warrants further studies with a larger patient population and correlation to neuropathological findings. Anticipation is a phenomenon associated with repeat expansion disorders. Furthermore, the size of the expansion correlates with the age of onset and disease severity to some extent. In reports on expanded *C9ORF72*, a trend towards genetic anticipation has been suspected \[[@B10],[@B22],[@B29]\]. However, as the current repeat-primed PCR method for the detection of *C9ORF72* expansion does not allow measurement of the repeat size, the phenomenon cannot be reliably studied.

The present study has some limitations. We could have added more value to genotype-phenotype correlations if each patient in the cohort had undergone a similar battery of investigations and the symptoms of the patients had been collected using a standard structured form. We might have missed some minor neuropsychiatric symptoms, as no standardised measurement of neuropsychiatric symptoms was used throughout the cohort. In the neuropsychological assessment, the heterogeneity of the patient cohort and the small number of patients did not allow the use of sample mean as a characteristic statistic. Furthermore, cognitive domains were used instead of reporting single test results, as no uniform neuropsychological test battery was employed. Lastly, visual analysis of brain MR images did not allow further conclusions to be drawn from the imaging results. Nevertheless, the results from the volumetric analyses are also difficult to translate into routine clinical practice \[[@B34]\], and thus our visual analyses are of value for clinical practice.

In conclusion, a wide range of demographic features as well as phenotype was found in our cohort of *C9ORF72* expansion carriers. A distinctive core phenotype for *C9ORF72*-positive FTLD has been suggested \[[@B10],[@B11]\]. Our results are mostly in line with this core phenotype showing a high frequency of neuropsychiatric symptoms. Yet, in our cohort, neuropsychiatric symptoms were not specific to *C9ORF72*-linked FTLD. The psychotic presentations, both in *C9ORF72* expansion carriers and non-carriers, suggest that FTLD should be considered in cases of middle-age-onset psychosis.
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![Neuropsychological features of the patients with *C9ORF72* repeat expansion. **a** Neuropsychological profile of a healthy individual. **b** Early cognitive profile in a subset of *C9ORF72* expansion carriers with bvFTD (n = 9). **c** Cognitive profile of all FTLD cases with expanded *C9ORF72* (n = 20). The results are displayed as modified McFie\'s target diagrams \[[@B35]\]. Each sector of the diagram shows a particular cognitive domain. Impairment of a domain was rated in five stages (0-4). In the patient diagrams, the level of function is presented with a group median value.](dee-0003-0251-g01){#F1}

![Examples of different patterns of atrophy in patients with *C9ORF72* repeat expansion. **a**, **b** Prominent frontal atrophy in patient No. 11, 2 years after symptom onset. **c** Relatively mild central atrophy in patient No. 20, 1 year after symptom onset. **d** Severe central atrophy with less prominent cortical atrophy in patient No. 15, 4 years after symptom onset. **e-g** Mild cortical atrophy in patients Nos. 14 (**e**, **f**) and 6 (**g**). At the time of imaging, patient No. 14 had suffered from symptoms of FTLD for 15 years. **g**, **h** Parietal cortical atrophy with small infarction on the left in patient No. 6, 3.5 years after symptom onset. Transaxial T2-weighted fluid-attenuated inversion recovery MR image (**a**, **c**, **e**, **g**). Coronal T1-weighted 3-dimensional MR image (**b**, **f**, **h**). Axial CT image (**d**).](dee-0003-0251-g02){#F2}

###### 

Summary of demographic and clinical characteristics of patients with *C90RF72* repeat expansion

  Patient No.   Sex   Clinical diagnosis   FTLD subtype   ALS onset   Family history   Age at onset, years   Age, years   Duration, years                   
  ------------- ----- -------------------- -------------- ----------- ---------------- --------------------- ------------ ----------------- --------------- ------
  1             F     FTLD                 bvFTD          --          No               No                    58           --                64 (current)    \>6
  2             M     FTLD                 bvFTD          --          Yes              No                    57           --                62 (current)    \>5
  3             F     FTLD                 bvFTD          --          Yes              No                    64           --                75 (current)    \>11
  4^a^          F     FTLD                 bvFTD          --          Yes              Yes                   60           --                72 (current)    \>12
  5             M     FTLD                 bvFTD          --          Yes              No                    54           --                66 (current)    \>12
  6^b^          F     FTLD                 bvFTD          --          Yes              No                    47           --                53 (current)    \>6
  7             F     FTLD                 bvFTD          --          No               No                    51           --                54 (current)    \>3
  8             M     FTLD                 bvFTD          --          Yes              No                    55           --                60 (current)    \>5
  9             M     FTLD                 bvFTD          --          Yes              No                    54           --                60 (current)    \>6
  10            M     FTLD                 bvFTD          --          Yes              No                    46           --                49 (current)    \>3
  11            F     FTLD                 bvFTD          --          Yes              No                    59           --                63 (current)    \>4
  12            M     FTLD                 bvFTD          --          Yes              Yes                   64           --                68 (current)    \>4
  13            F     FTLD                 PNFA           --          No               No                    60           --                71 (at death)   11
  14            M     FTLD                 PNFA           --          No               No                    51           --                70 (current)    \>19
  15            M     FTLD                 PNFA           --          No               No                    64           --                71 (at death)   7
  16            F     FTLD                 PNFA           --          Yes              No                    63           --                72 (at death)   9
  17            F     FTLD-ALS             bvFTD          bulbar      No               No                    59           60                62 (at death)   3
  18            F     FTLD-ALS             PNFA           bulbar      No               Yes                   54           55                58 (at death)   4
  19            M     FTLD-ALS             PNFA           bulbar      Yes              No                    70           70                71 (at death)   1
  20            M     FTLD-ALS             bvFTD          bulbar      No               No                    57           57                60 (at death)   3
  21            F     FTLD-ALS             bvFTD          spinal      No               No                    60           60                63 (at death)   3
  22            F     FTLD-ALS             bvFTD          bulbar      No               No                    66           66                69 (at death)   3

The sibling is patient No.12, patient No. 4 was excluded from the association analysis.

The sibling is patient No. 5, patient No. 6 was excluded from the association analysis.

###### 

Clinical comparison between groups of FTLD patients with and without expanded *C90RF72*

  Variable                                             Non-expanded *C90RF72* (n = 50)   Expanded *C90RF72* (n = 20)   p value   Crude OR (95% CI)    Adjusted OR (95% CI)
  ---------------------------------------------------- --------------------------------- ----------------------------- --------- -------------------- ------------------------------------------------------
  Age at onset, years                                  58.8 ± 7.9                        58.3 ± 5.9                    0.81                           
   Range, years                                        38 -- 79                          46 -- 70                      --                             
  Survival, years[^a^](#T2F1){ref-type="table-fn"}     13.8 ± 0.8                        14.0 ± 2.1                    0.92                           
  Male/female (male %)                                 22/28 (44)                        10/10 (50)                    0.65                           
  FTLD phenotype                                                                                                                                      
   Behavioural variant                                 29 (58)                           14 (70)                       0.35                           
   Language variant[^b^](#T2F2){ref-type="table-fn"}   21 (42)                           6 (30)                        --                             
  Concomitant ALS                                      2 (4)                             6 (30)                        0.005\*   10.3 (1.9 -- 56.7)   16.4 (2.6 -- 104.1)[^d^](#T2F4){ref-type="table-fn"}
  Positive family history                                                                                                                             
   Dementia or ALS                                     13 (26)                           11 (55)                       0.02\*    3.5 (1.2 -- 10.3)    5.2 (1.5 -- 17.9)[^d^](#T2F4){ref-type="table-fn"}
   Dementia                                            13 (26)                           10 (50)                       0.05      2.8 (1.0 -- 8.4)     
   ALS                                                 0 (0)                             2 (10)                        NA                             
  MMSE at referral[^c^](#T2F3){ref-type="table-fn"}    22.9 ± 4.6                        24.3 ± 4.8                    0.31                           

Values are numbers (%) unless otherwise specified. Continuous variables are shown as mean ± SD. NA = Not applicable. Statistically significant: \* p \< 0.05.

Survival from symptom onset to death. Patients with concomitant ALS were excluded. Data included censored data (11 for *C90RF72* expansion carriers and 33 for non-carriers).

PNFA + SD.

MMSE score 0 -- 30. Data available for 16 expansion carriers and 46 non-carriers.

Adjusted for concomitant ALS and positive family history of dementia or ALS.

###### 

Neuropathological findings, including detailed immunohistochemical results (p62 and p-TDP-43), for 2 cases (Nos. 16 and 17) with and 1 case (No. 23) without *C90RF72* expansion

                              Patient No.                       
  --------------------------- ------------- --------- --------- --
  *IHC p62/p-TDP-43^a^*                                         
  Frontal cortex                                                
   NCI                        +/+           ++/+++    +/+++     
   DN                         +/++          --/+++    (+)/++    
  Temporal cortex                                               
   NCI                        +/+           (+)/++    (+)/++    
   DN                         +/++          --/+++    --/++     
  Hippocampus                                                   
   Pyramidal NCI              (+)/+         +/+       --/(+)    
   Granular NCI               +++/++        +++/+++   ++/++     
   DN                         --/--         --/--     --/--     
  Cerebellum                                                    
   Purkinje cells             --/--         --/--     --/--     
   Dentate neurons            --/--         --/--     --/--     
   Molecular layer NCI        ++/--         +/--      --/--     
   Granular layer NCI         +++/--        ++/--     --/--     
   DN                         --/--         --/--     --/--     
   GCI                        --/--         --/(+)    --/(+)    
  Brain stem                                                    
   ON pyramidal NCI           +/++          --/+      ++/++     
   HN/VN pyramidal NCI        (+)/--        --/--     (+)/+++   
   DN                         --/+          --/--     --/--     
   GCI                        --/--         (+)/(+)   --/--     
  Spinal cord anterior horn                                     
   NCI                        --/--         --/+      +/++      
   DN                         --/--         --/--     --/--     
   GCI                        --/--         (+)/(+)   +/+       
                                                                
  FTLD-TDP type^b^            B             A         A         

DN = Dystrophic neurites; GCI = glial cytoplasmic inclusions; HN = hypoglossal nucleus; IHC = immunohistochemistry; ON = olivary nucleus; VN = vagal nucleus.

IHC was scored using a semiquantitative grading system: -- negative; (+) occasional; + few; ++ moderate; +++ numerous.

Subtyped according to the harmonised classification system for FTLD-TDP pathology (type A--D) \[[@B20]\].
